Clinical Significance of Serum Vascular Endothelial Growth Factor, Pigment Epithelium–Derived Factor, Tumor Necrosis Factor Alpha, and Progranulin Levels in Patients with Gastric Cancer and Gastric Precancerous Lesions
- 73 Downloads
The purpose of this study is to evaluate serum levels of vascular endothelial growth factor (VEGF), pigment epithelium–derived factor (PEDF), tumor necrosis factor alpha (TNF-α), and progranulin in patients with gastric cancer (GC) and precancerous lesions (PCL) and to determine the usefulness of these markers as diagnostic biomarkers in these diseases.
A total of 32 GC patients, 35 PCL patients, and 23 healthy controls participated in the study. The serum levels of VEGF, PEDF, TNF-α, and progranulin were measured by enzyme-linked immunosorbent assay (ELISA).
The mean serum VEGF levels were 30.6 ± 12.98 pg/mL in GC, 18.2 ± 5.72 pg/mL in PCL, and 17.5 ± 5.59 pg/mL in controls. GC VEGF levels were significantly higher than both PCL and control groups (p < 0.001). The mean serum PEDF levels were 1516.1 ± 993.8 pg/mL in GC, 1039.1 ± 1002.3 pg/mL in PCL, and 767.5 ± 661.5 pg/mL in controls. The serum PEDF level in the GC group was significantly higher than that in both PCL and control groups (p = 0.004 and p = 0.038, respectively). The mean serum TNF-α levels were 46.7 ± 14.82 pg/mL in GC, 38.4 ± 11.89 pg/mL in PCL, and 33.8 ± 12.77 pg/mL in controls. There was a significant difference between GC and controls (p = 0.022) in TNF-α levels. The mean serum progranulin levels in GC were 2496.6 ± 737.8 pg/mL, 2332.0 ± 482.1 pg/mL in PCL, and 1288.7 ± 830.9 pg/mL in controls. Progranulin levels in both GC and PCL groups were significantly higher than that in the control group (p < 0.001 for both).
There were significant differences among patients with GC and PCL and healthy controls in terms of serum VEGF, PEDF, TNF-α, and progranulin levels.
KeywordsGastric cancer Gastric atrophy Intestinal metaplasia VEGF PEDF TNF-α Progranulin
Compliance with Ethical Standards
All procedures performed involving human participants were in accordance with the ethical standards of the institutional research committee (Keçiören Training and Research Hospital with reference number 01.2018/1601) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide. 2012, http://globocan.iarc. fr/Pages/fact_sheets_cancer. aspx (accessed June 20, 2016).
- 5.Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6. https://doi.org/10.1056/NEJM197111182852108.
- 11.Demorrow S. Progranulin: a novel regulator of gastrointestinal cancer progression. Transl Gastrointest Cancer. 2013 Jul;2(3):145–51. https://doi.org/10.3978/j.issn.2224-4778.2013.02.02.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Wang XY, Wang LL, Zheng X, Meng LN, Lyu B, Jin HF. Expression of p-STAT3 and vascular endothelial growth factor in MNNG induced precancerous lesions and gastric tumors in rats. World J Gastrointest Oncol. 2016;8(3):305–13. https://doi.org/10.4251/wjgo.v8.i3.305.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Yakut M, Örmeci N, Erdal H, Keskin O, Karayel Z, Tutkak H, et al. The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 beta, serum toll-like receptor-4 levels and Helicobacter pylori cag A status. Clin Res Hepatol Gastroenterol. 2013;37(3):302–11. https://doi.org/10.1016/j.clinre.2012.09.013.CrossRefPubMedGoogle Scholar
- 17.Senthilkumar C, Niranjali S, Jayanthi V, Ramesh T, Devaraj H. Molecular and histological evaluation of tumor necrosis factor-alpha expression in Helicobacter pylori-mediated gastric carcinogenesis. J Cancer Res Clin Oncol. 2011;137(4):577–83. https://doi.org/10.1007/s00432-010-0921-9.CrossRefPubMedGoogle Scholar
- 18.Sánchez-Zauco N, Torres J, Gómez A, Camorlinga-Ponce M, Muñoz-Pérez L, Herrera-Goepfert R, et al. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study. BMC Cancer. 2017;17(1):384. https://doi.org/10.1186/s12885-017-3310-9. CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Erturk K, Tastekin D, Serilmez M, Bilgin E, Bozbey HU, Vatansever S. Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer. Tumour Biol. 2016;37(1):405–12. https://doi.org/10.1007/s13277-015-3829-9.CrossRefPubMedGoogle Scholar